Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro

Transplantation

Volumn 76, Issue 12, 2003, Pages 1735-1741

  Blaheta, Roman A ^a,b   Bogossian, Harilaos ^a   Beecken, Wolf Dietrich ^a   Jonas, Dietger ^a   Hasenberg, Christoph ^a   Makarevic, Jasmina ^a   Ogbomo, Henry ^a   Bechstein, Wolf O ^a   Oppermann, Elsie ^a   Leckel, Kerstin ^a   Cinatl Jr , Jindrich ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NERVE CELL ADHESION MOLECULE; PROTEIN; RNA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CANCER INVASION; CANCER RECURRENCE; CELL ADHESION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; MONOLAYER CULTURE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; UMBILICAL VEIN; WESTERN BLOTTING;

BASE SEQUENCE; CELL ADHESION; CELLS, CULTURED; COCULTURE TECHNIQUES; DNA PRIMERS; ENDOTHELIUM, VASCULAR; HUMANS; KINETICS; MYCOPHENOLIC ACID; NEURAL CELL ADHESION MOLECULES; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 9144240743     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000092004.83992.B2     Document Type: Article

References (30)

1. Blaheta RA, Leckel K, Wittig B, et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl Immunol 1998; 6: 251.
2. Raab M, Daxecker H, Karimi A, et al. In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clin Chim Acta 2001; 310: 89.
3. Hunter I, Sawa H, Edlund M, et al. Evidence for regulated dimerization of cell-cell adhesion molecule (C-CAM) in epithelial cells. Biochem J 1996; 320: 847.
4. Guttinger M, Sutti F, Panigada M, et al. Epithelial V-like antigen (EVA), a novel member of the immunoglobulin superfamily, expressed in embryonic epithelia with a potential role as homotypic adhesion molecule in thymus histogenesis. J Cell Biol 1998; 141: 1061.
5. Nelissen JM, Peters IM, de Grooth BG, et al. Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. Mol Biol Cell 2000; 11: 2057.
6. Trebak M, Begg GE, Chong JM, et al. Oligomeric state of the colon carcinoma-associated glycoprotein GA733-2 (Ep-CAM/EGP40) and its role in GA733-mediated homotypic cell-cell adhesion. J Biol Chem 2001; 276: 2299.
7. Blaheta RA, Hundemer M, Mayer G, et al. Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell Commun Adhes 2003; 9: 131.
8. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: A population-based study. J Hepatol 2001; 34: 84.
9. Reeves ME. A metastatic tumor cell line has greatly reduced levels of a specific homotypic cell adhesion molecule activity. Cancer Res 1992; 52: 1546.
10. Owens GC, Orr EA, DeMasters BK, et al. Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. Cancer Res 1998; 58(9): 2020.
11. Edvardsen K, Pedersen P-H, Bjerkvig R, et al. Transfection of glioma cells with the neural-cell adhesion molecule NCAM: Effect on glioma cell invasion and growth in vivo. Int J Cancer 1994; 58: 116.
12. Cinatl J Jr, Cinatl J, Scholz M, et al. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 1996; 7: 766.
13. Kotchetkov R, Cinatl J, Blaheta R, et al. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model. Int J Cancer 2003; 104: 36.
14. Wittig BM, Thees R, Kaulen H, et al. Alpha(1,3) fucosyltransferase expression in E-selectin-mediated binding of gastrointestinal tumor cells. Int J Cancer 1996; 67: 80.
15. Kiselyov V, Berezin V, Maar TE, et al. The first immunoglobulin-like neural cell adhesion molecule (NCAM) domain is involved in double-reciprocal interaction with the second immunoglobulin-like NCAM domain and in heparin binding. J Biol Chem 1997; 272: 10125.
16. Prag S, Lepekhin EA, Kolkova K, et al. NCAM regulates cell motility. J Cell Sci 2002; 115: 283.
17. Huerta S, Srivatsan ES, Venkatesan N, et al. Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. Surgery 2001; 130: 834.
18. Roesler J, Srivatsan E, Moatamed F, et al. Tumor suppressor activity of neural cell adhesion molecule in colon carcinoma. Am J Surg 1997; 174: 251.
19. Sampson-Johannes A, Wang W, Shtivelman E. Colonization of human lung grafts in SCID-hu mice by human colon carcinoma cells. Int J Cancer 1996; 65: 864.
20. Cavallaro U, Niedermeyer J, Fuxa M, et al. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001; 3: 650.
21. Perl AK, Dahl U, Wilgenbus P, et al. Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells. Nat Med 1999; 5: 286.
22. Tezel E, Kawase Y, Takeda S, et al. Expression of neural cell adhesion molecule in pancreatic cancer. Pancreas 2001; 22: 122.
23. Huerta S, Srivatsan ES, Venkatasan N, et al. Human colon cancer cells deficient in DCC produce abnormal transcripts in progression of carcinogenesis. Dig Dis Sci 2001; 46: 1884.
24. Yoshida Y, Itoh F, Endo T, et al. Decreased DCC mRNA expression in human gastric cancers is clinicopathologically significant. Int J Cancer 1998; 79: 634.
25. Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 1999; 104: 138.
26. Dahl IM, Rasmussen T, Kauric G, et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002; 116: 273.
27. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12: 1977.
28. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients: Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1995; 90: 106.
29. Kaiser U, Oldenburg M, Jaques G, et al. Soluble CD56 (NCAM): A new differential-diagnostic and prognostic marker in multiple myeloma. Ann Hematol 1996; 73: 121.
30. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002; 117: 882.